Analyst Ratings For Audentes Therapeutics (NASDAQ:BOLD)
Today, Wedbush reiterated its Outperform rating on Audentes Therapeutics (NASDAQ:BOLD) with a price target of $56.00.
Some recent analyst ratings include
- 3/9/2018-Wedbush Reiterated Rating of Outperform.
- 3/9/2018-William Blair Reiterated Rating of Buy.
- 2/12/2018-Mizuho initiated coverage with a Neutral rating.
- 1/4/2018-Raymond James Financial Reiterated Rating of Hold.
- 11/15/2017-Leerink Swann Reiterated Rating of Outperform.
Recent Insider Trading Activity For Audentes Therapeutics (NASDAQ:BOLD)
Audentes Therapeutics (NASDAQ:BOLD) has insider ownership of 47.30% and institutional ownership of 67.35%.
- On 3/6/2018 Orbimed Advisors Llc, Major Shareholder, sold 433,210 with an average share price of $35.11 per share and the total transaction amounting to $15,210,003.10.
- On 3/2/2018 Orbimed Advisors Llc, Major Shareholder, sold 421,638 with an average share price of $35.17 per share and the total transaction amounting to $14,829,008.46.
- On 12/22/2017 Louis G Lange, Director, sold 18,000 with an average share price of $30.88 per share and the total transaction amounting to $555,840.00.
- On 12/1/2017 Suyash Prasad, VP, sold 8,000 with an average share price of $28.53 per share and the total transaction amounting to $228,240.00.
- On 11/16/2017 Mary Newman, SVP, sold 10,000 with an average share price of $26.84 per share and the total transaction amounting to $268,400.00.
- On 10/2/2017 Matthew R Patterson, CEO, sold 25,000 with an average share price of $27.92 per share and the total transaction amounting to $698,000.00.
- On 9/29/2017 Louis G Lange, Director, sold 11,000 with an average share price of $28.35 per share and the total transaction amounting to $311,850.00.
Recent Trading Activity for Audentes Therapeutics (NASDAQ:BOLD)
Shares of Audentes Therapeutics closed the previous trading session at 34.30 down -0.12 0.36% with 34.0099983215332 shares trading hands.
